Harold Bernstein, President, R&D & CMO at Maze Therapeutics, Inc. (MAZE), sold 45,000 shares at $40.93 ($1.8M) on 2025-12-29, disclosed to the SEC on 2025-12-31.
Scheduled sale ($1.8M) by President, R&D & CMO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $40.34 | 27,800 | $1.1M | 61.4% |
| 2 | $40.93 | 17,200 | $704K | 38.6% |
| Total | $40.57 avg | 45,000 | $1.8M | 100% |
| Filing → |
| MAZE | SELL | 2026-09-04 | $270K | — | Filing → |
| MAZE | SELL | 2026-09-03 | $426K | — | Filing → |
| MAZE | SELL | 2026-08-14 | $446K | — | Filing → |